NASDAQ:SHPH Shuttle Pharmaceuticals (SHPH) Stock Price, News & Analysis → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free SHPH Stock Alerts $0.53 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.50▼$0.5950-Day Range$0.39▼$0.5352-Week Range$0.35▼$1.27Volume568,030 shsAverage Volume36,622 shsMarket Capitalization$8.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Shuttle Pharmaceuticals alerts: Email Address Ad Weiss RatingsOn June 10, Nvidia makes its next big moveA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. About Shuttle Pharmaceuticals Stock (NASDAQ:SHPH)Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.Read More SHPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SHPH Stock News HeadlinesMay 29 at 6:58 AM | americanbankingnews.comShuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest UpdateMay 23, 2024 | americanbankingnews.comShuttle Pharmaceuticals (NASDAQ:SHPH) Stock Price Down 2.4%May 22, 2024 | globenewswire.comShuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 14, 2024 | finanznachrichten.deShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides First Quarter 2024 Corporate UpdateMay 14, 2024 | globenewswire.comShuttle Pharma Provides First Quarter 2024 Corporate UpdateMay 13, 2024 | investorplace.comSHPH Stock Earnings: Shuttle Pharmaceuticals Reported Results for Q1 2024April 23, 2024 | globenewswire.comShuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024April 3, 2024 | globenewswire.comShuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024March 22, 2024 | finanznachrichten.deShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Fourth Quarter 2023 Corporate UpdateMarch 22, 2024 | finance.yahoo.comShuttle Pharma Provides Fourth Quarter 2023 Corporate UpdateMarch 22, 2024 | msn.comSHPH Stock Earnings: Shuttle Pharmaceuticals Reported Results for Q4 2023March 5, 2024 | globenewswire.comShuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024February 13, 2024 | finance.yahoo.comShuttle Pharma Announces Its Intent to Pursue a Rights OfferingFebruary 6, 2024 | msn.comShuttle Pharmaceuticals Acquires Promising Prostate Cancer TechnologyFebruary 6, 2024 | msn.comShuttle Pharmaceuticals Bolsters Investor Relations with New PartnershipJanuary 23, 2024 | finance.yahoo.comShuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024January 8, 2024 | finance.yahoo.comShuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaDecember 11, 2023 | finance.yahoo.comShuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaNovember 30, 2023 | finance.yahoo.comShuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023November 14, 2023 | msn.comShuttle Pharmaceuticals reports Q3 resultsNovember 14, 2023 | finance.yahoo.comShuttle Pharmaceuticals Provides Third Quarter 2023 Corporate UpdateOctober 31, 2023 | finance.yahoo.comShuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License AgreementOctober 10, 2023 | finance.yahoo.comShuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor ConferenceSeptember 25, 2023 | marketwatch.comShuttle Pharma Gets FDA Letter With Positive Feedback for RopidoxuridineSeptember 25, 2023 | finance.yahoo.comShuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaSee More Headlines Receive SHPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shuttle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/01/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SHPH CUSIPN/A CIK1757499 Webwww.shuttlepharma.com Phone240-403-4212FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-151.82% Return on Assets-109.20% Debt Debt-to-Equity RatioN/A Current Ratio2.96 Quick Ratio2.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book3.32Miscellaneous Outstanding Shares16,795,000Free Float9,976,000Market Cap$8.92 million OptionableNot Optionable Beta-1.18 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Anatoly Dritschilo M.D. (Age 80)Co-Founder, CEO & Chairman of the Board Comp: $399.18kMr. Peter Dale Dritschilo M.B.A. (Age 55)M.D., President & COO Comp: $314.01kDr. Milton Brown CSC (Age 59)M.D., Ph.D., Co-Founder & Director Mr. Michael P. Vander Hoek (Age 64)CFO and VP of Operations & Regulatory Comp: $302.53kDr. Tyvin A. Rich M.D. (Age 76)Chief Clinical Officer & Chief Medical Officer Comp: $263.23kDr. Mira Jung Ph.D. (Age 75)Co-Founder & Chief Scientific Officer for Biology Mr. Gene Jung Esq.General CounselMore ExecutivesKey CompetitorsImmunoPrecise AntibodiesNASDAQ:IPAJanOneNASDAQ:JANSpruce BiosciencesNASDAQ:SPRBOncternal TherapeuticsNASDAQ:ONCTBioVieNASDAQ:BIVIView All CompetitorsInsidersBette JacobsSold 4,157 sharesTotal: $1,912.22 ($0.46/share)View All Insider Transactions SHPH Stock Analysis - Frequently Asked Questions How have SHPH shares performed in 2024? Shuttle Pharmaceuticals' stock was trading at $0.4550 at the start of the year. Since then, SHPH stock has increased by 16.7% and is now trading at $0.5310. View the best growth stocks for 2024 here. Are investors shorting Shuttle Pharmaceuticals? Shuttle Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 40,800 shares, a decline of 41.5% from the April 30th total of 69,800 shares. Based on an average daily volume of 41,500 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.4% of the company's shares are short sold. View Shuttle Pharmaceuticals' Short Interest. When is Shuttle Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our SHPH earnings forecast. How were Shuttle Pharmaceuticals' earnings last quarter? Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) released its earnings results on Monday, May, 13th. The company reported ($0.10) EPS for the quarter. When did Shuttle Pharmaceuticals IPO? Shuttle Pharmaceuticals (SHPH) raised $10 million in an initial public offering (IPO) on Wednesday, August 31st 2022. The company issued 1,225,888 shares at $8.13 per share. How do I buy shares of Shuttle Pharmaceuticals? Shares of SHPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SHPH) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyNvidia is about to pass AppleWeiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shuttle Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
